In:
Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 30, No. 15_suppl ( 2012-05-20), p. 5063-5063
Abstract:
5063 Background: There is emerging data in different malignancies, including gynecologic cancers, demonstrating factors independent of a patient’s tumor characteristics, which are associated with an increased risk of cancer recurrence. The goal of this study is to determine demographic and prognostic factors affecting recurrence of disease (RD) in women with ovarian granulosa cell tumors (GCT). Methods: A dual-institution retrospective analysis of patients diagnosed with GCT between 1995 and 2010. Demographics including age, race, BMI, stage, diabetes (DM), adjuvant treatment, and progression free survival (PFS) were extracted. Hazard ratios for recurrence were estimated by univariate and multivariate Cox regression models Results: One hundred nine women identified with a median age of 50 (range 12-87). Fifty-six (57.1%) were Caucasian, 32 (32.7%) African American, and 10 (10.2%) were other. Median BMI was 29 (range 12-57). Twenty-one patients had DM. The majority of women had stage I disease (89.0%), 7 (6.4%) had stage II/III disease, and 5 were unstaged. In univariate analysis, DM showed the strongest association with recurrence (HR 3.56, 95% CI: 1.57-8.11). Non-white race was also associated with higher risk of RD, though the association was not statistically significant (HR 1.74, 95% CI: 0.78-3.87). The association between DM and RD was also found in multivariate analysis controlling for all factors including non-white race and BMI (HR 2.99, 95% CI: 1.11-8.08). Only 19 (17%) patients received adjuvant chemotherapy consisting of one of two different adjuvant chemotherapy regimens bleomycin, etoposide, and cisplatin or paclitaxel and carboplatin, however there was no difference in outcome based on chemotherapy regimen (p=0.24). Conclusions: This is the largest study analyzing factors associated with risk of recurrence in women with ovarian GCT. Studies have demonstrated higher morbidity among diabetic patients with breast and colon cancer and this may be modifiable with metformin. Our results emphasize that diabetes is one of the strongest predictors of recurrent disease in patients with ovarian GCT. Further studies are necessary to evaluate the effect of other factors such as adjuvant chemotherapy.
Type of Medium:
Online Resource
ISSN:
0732-183X
,
1527-7755
DOI:
10.1200/jco.2012.30.15_suppl.5063
Language:
English
Publisher:
American Society of Clinical Oncology (ASCO)
Publication Date:
2012
detail.hit.zdb_id:
2005181-5
Bookmarklink
